PT - JOURNAL ARTICLE AU - Everett, Selin S. AU - Bomback, Miles AU - Sahni, Rakesh AU - Wapner, Ronald J. AU - Tolia, Veeral N. AU - Clark, Reese H. AU - Lyford, Alex AU - Hays, Thomas TI - Prevalence and Clinical Significance of Commonly Diagnosed Genetic Disorders in Preterm Infants AID - 10.1101/2023.07.14.23292662 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.14.23292662 4099 - http://medrxiv.org/content/early/2023/07/16/2023.07.14.23292662.short 4100 - http://medrxiv.org/content/early/2023/07/16/2023.07.14.23292662.full AB - Preterm infants (<34 weeks gestation) experience high rates of morbidity and mortality before hospital discharge. Genetic disorders substantially contribute to morbidity and mortality in related populations. The prevalence and clinical impact of genetic disorders is unknown in this population. We sought to determine the prevalence of commonly diagnosed genetic disorders in preterm infants, and to determine the association of disorders with morbidity and mortality. This was a retrospective multicenter cohort study of infants born from 23 to 33 weeks gestation between 2000 and 2020. Genetic disorders were abstracted from diagnoses present in electronic health records. We excluded infants transferred from or to other health care facilities prior to discharge or death when analyzing clinical outcomes. We determined the adjusted odds of pre-discharge morbidity or mortality after adjusting for known risk factors. Of 409,704 infants, 5838 (1.4%) had genetic disorders. Infants with trisomy 13, 18, 21, or cystic fibrosis had greater adjusted odds of severe morbidity or mortality. Of the 17,427 infants who died, 566 (3.2%) had genetic disorders. Of the 65,968 infants with a severe morbidity, 1319 (2.0%) had genetic disorders. Our work demonstrates that genetic disorders are prevalent in preterm infants, especially those with life-threatening morbidities. Clinicians should consider genetic testing for preterm infants with severe morbidity and maintain a higher index of suspicion for life-threatening morbidities in preterm infants with genetic disorders. Prospective genomic research is needed to clarify the prevalence of genetic disorders in this population, and the contribution of genetic disorders to preterm birth and subsequent morbidity and mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthor TH is supported by two career development awards: the Thrasher Research Fund Early Career Award and the NIH National Center for Advancing Translational Sciences (KL2TR001874).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of Columbia University with a waiver for informed consent (IRB Protocol #AAAT2607).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.